A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorAdventHealth

About this trial

The purpose of this study is to collect data to evaluate safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in hepatopancreatic biliary (HPB) and Foregut operations. HPB and Foregut operations of this study consist of cholecystectomy, fundoplication, gastrectomy, distal pancreatectomy, pancreaticoduodenectomy, esophagectomy, and hepatectomy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients between the ages of 18 and 80 years of age

Either male or female

BMI ≤ 26 kg/m2

ASA ≤ 3

Disqualifiers

Subject requiring an emergent operation

Pregnancy or nursing

BMI > 26 kg/m2

Previous abdominal surgery

Trial design

Design model

Single group

Treatments tested in this trial

  • da Vinci SP® Single-Port Robotic Surgical System

    Device

    The da Vinci SP® Surgical System is designed to enable the performance of surgical procedures using a minimally invasive single-port approach. The system consists of a Surgeon Console, a Vision Cart, and a Patient Cart and is used with a camera, instruments, and accessories.

Treatment groups

35 Participants
are divided into 1 treatment group
Group A: da Vinci SP® Single-Port Robotic Surgical SystemExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Completion Using the planned da Vinci SP-assisted Single Port Robot.

The number of subjects who completed the planned da Vinci SP-assisted operation without conversion to an alternate approach. Conversion to an alternate approach comprises conversion to open, multiport laparoscopic, multiport robotic or hand-assisted approach requiring undocking of the da Vinci SP Surgical System in order to complete the planned operation using the alternate approach.

Time frame
12 months
2

Intraoperative and post-operative adverse events

The incidence of all intraoperative and post-operative adverse events that occur through the 24-month follow-up period.

Time frame
24 months
3

Number of Positive resection Margins

Number of positive resection margins in patients with Malignant disease.

Time frame
24 months
4

Number of Lymph node yield

Number of lymph node yield in patients with Malignant disease.

Time frame
24 Months

Secondary outcomes

1

Physical Status Classification

Assessment of the fitness of patient before surgery using the ASA Physical Status Score: Class I - A patient in normal health Class II - A patient with mild systemic disease resulting in no functional limitations Class III - A patient with severe systemic disease that limits activity, but is not incapacitating Class IV - A patient with severe systemic disease that is a constant threat to life Class V - A moribund patient not likely to survive without the operation Class VI - A patient already declared brain dead whose organs are being removed for donor purposes

Time frame
Pre-Operative Visit
2

Charlson Comorbidity Index Score

Predicts one-year mortality for patients with a range of comorbid conditions, helping the physician determine how aggressively to treat a condition. This index score is assessed by assigning points (1,2,3 or 6) based on the likelihood of dying associated to 17 different conditions (co-morbidities). Scores are summed to provide a total score to predict mortality. Comorbidity classification is categorized as low (score ≤ 3), moderate (score 4 and 5), high (score 6 and 7), and very high comorbidity (score ≥ 8)

Time frame
Pre-Operative Visit
3

Operative Time

Measured in minutes

Time frame
Intraoperative
4

Estimated blood loss

Measured after surgery in milliliters of blood. Estimated based on blood infusion volume during the surgery.

Time frame
Intraoperatively

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.